Table 1.
In-vitro antibacterial activity of 2-salicyloylbenzofuran derivatives.
| Compound b | Zone of Inhibition in mm (MIC in mM) a | |||
|---|---|---|---|---|
| E. coli | S. faecalis | MSSA | MRSA | |
| 4 | 9.5 (>2.50) | 9.5 (>2.50) | – | – |
| 5 | – | 9 (>2.59) | 10 (>2.59) | 13 (>2.59) |
| 7a | 8 (>2.41) | – | – | 12 (>2.41) |
| 7b | 8 (>2.35) | – | 12 (2.35) | 16 (2.35) |
| 7c | – | – | – | – |
| 7d | 8(>1.97) | – | – | 14 (>1.97) |
| 7e | 8 (>1.84) | – | 18 (>1.84) | – |
| 7f | – | – | – | 8 (>2.12) |
| 8f | – | 12 (0.28) | 16 (0.14) | 14 (0.14) |
| 8g | – | 11 (0.55) | 19 (0.27) | 17 (0.27) |
| 8h | – | 15 (0.12) | 17 (0.06) | 15 (0.12) |
| 14a | – | – | 10 (0.86) | 11 (>3.46) |
| 14b | – | – | 9 (1.65) | 9 (3.30) |
| 14c | – | 9 (3.14) | 9 (1.57) | 9 (1.57) |
| 14d | 9 (3.10) | 9 (>3.10) | 9 (1.55) | 10 (1.55) |
| 14e | – | 9 (2.73) | 9 (1.36) | 11 (1.36) |
| 14f | – | 11 (1.40) | 9 (0.70) | 11 (0.70) |
| Ampicillin | 35 (0.006) | 28 (0.006) | 31 (0.0007) | 15 (0.05) |
| Cefuroxime | 33 (0.02) | – | 31 (0.02) | 25 (0.04) |
| Vancomycin | 23 (0.0014) | 30 (0.00004) | 30 (0.00004) | 31 (0.00004) |
a E. coli: Escherichia coli ATCC 25922; S. faecalis: Streptococcus faecalis ATCC 29212; MSSA: methicillin-sensitive Staphylococcus aureus ATCC 29213; MRSA: methicillin-resistant Staphylococcus aureus ATCC 43300; b other compounds: not tested; (–): not inhibition at tested concentration.